When Medicine is Not Enough for Schizophrenia and Psychosis
Tuesday, July 12, 2022, 2:00 pm EDT
Many individuals experience continued symptoms for Schizophrenia and Psychosis despite the best medication treatments available. What are some of the therapy approaches that can help when medicine is not enough? How do these approaches work?
Watch webinar recording:
Please use #BBRFWebinar when sharing or posting about our Meet the Scientist Webinars on social media.
Director, Division of Community Recovery, Research and Training
Henry B. Dielmann Chair, Department of Psychiatry
University of Texas Health Science Center in San Antonio
2016 Distinguished Investigator Grant
2002 Independent Investigator Grant
1997 Young Investigator Grant
Dawn I. Velligan, Ph.D., of the University of Texas Health Science Center at San Antonio, will look for new biomarkers that are associated with particularly severe cases of schizophrenia. These markers will be used to assess a new treatment, known as the MOtiVation and Engagement (MOVE) Program. The method builds on existing therapies with comprehensive, home-based, multi-modal approaches, and results have been promising so far. Dr. Velligan will focus on inflammatory markers as potential biomarkers. He will examine the relationship between the amount of inflammatory markers circulating in the blood of patients and the severity of their negative symptoms. Dr. Velligan will also assess the impact of MOVE on levels of these molecules. This work has the potential to uncover novel biomarkers associated with the negative symptoms of schizophrenia, which may offer a path to more targeted, improved treatments.
Jeffrey Borenstein, M.D., serves as the President & CEO of the Brain & Behavior Research Foundation, the largest private funder of mental health research grants. Dr. Borenstein developed the Emmy-nominated public television program “Healthy Minds,” and serves as host and executive producer of the series. The program, broadcast nationwide, is available online, and focuses on topics in psychiatry in order to educate the public, reduce stigma and offer a message of hope. Dr. Borenstein served as Editor-in-Chief of Psychiatric News, the newspaper of the American Psychiatric Association from 2012 - 2023.
Dr. Borenstein is a Fellow of the New York Academy of Medicine and serves as the Chair of the Section of Psychiatry at the Academy. He also has served as the President of the New York State Psychiatric Association. Dr. Borenstein earned his undergraduate degree at Harvard and his medical degree at New York University.
